死亡受体作为癌症治疗的靶点。
Death receptors as targets in cancer.
机构信息
UMR866, INSERM, Dijon, France.
出版信息
Br J Pharmacol. 2013 Aug;169(8):1723-44. doi: 10.1111/bph.12238.
Abstract
UNLABELLED
Anti-tumour therapies based on the use pro-apoptotic receptor agonists, including TNF-related apoptosis-inducing ligand (TRAIL) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast majority of these compounds, whether combined or not with conventional or targeted anti-cancer therapies. This brief review aims at discussing the possible reasons for the lack of apparent success of these therapeutic approaches and at providing hints in order to rationally design optimal protocols based on our current understanding of TRAIL signalling regulation or resistance for future clinical trials.
LINKED ARTICLES
This article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-8.
摘要
无标签
基于使用促凋亡受体激动剂的抗肿瘤疗法，包括 TNF 相关凋亡诱导配体（TRAIL）或针对 TRAIL-R1 或 TRAIL-R2 的单克隆抗体，尽管这些化合物绝大多数都有明确的临床活性和无不良事件的证据，无论是联合还是不联合常规或靶向抗癌疗法，迄今为止都令人失望。这篇简短的综述旨在讨论这些治疗方法缺乏明显成功的可能原因，并提供一些提示，以便根据我们目前对 TRAIL 信号转导调节或耐药性的理解，为未来的临床试验设计最佳方案。
相关文章
本文是肿瘤学新兴治疗方面专题的一部分。要查看本部分中的其他文章，请访问 http://dx.doi.org/10.1111/bph.2013.169.issue-8。
相似文献
1
Death receptors as targets in cancer.死亡受体作为癌症治疗的靶点。
Br J Pharmacol. 2013 Aug;169(8):1723-44. doi: 10.1111/bph.12238.
2
TRAIL receptor signalling and modulation: Are we on the right TRAIL?肿瘤坏死因子相关凋亡诱导配体（TRAIL）受体信号传导与调节：我们是否选对了TRAIL？
Cancer Treat Rev. 2009 May;35(3):280-8. doi: 10.1016/j.ctrv.2008.11.006. Epub 2008 Dec 30.
3
TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.基于 TRAIL 的治疗方法治疗儿科恶性肿瘤。
Curr Med Chem. 2013;20(17):2254-71. doi: 10.2174/0929867311320170009.
4
Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts.西妥昔单抗通过促进脂筏中的 DISC 形成增强 TRAIL 诱导的胃癌细胞凋亡。
Biochem Biophys Res Commun. 2013 Sep 20;439(2):285-90. doi: 10.1016/j.bbrc.2013.08.040. Epub 2013 Aug 21.
5
The TRAIL apoptotic pathway in cancer onset, progression and therapy.肿瘤坏死因子相关凋亡诱导配体（TRAIL）凋亡通路在癌症发生、发展及治疗中的作用
Nat Rev Cancer. 2008 Oct;8(10):782-98. doi: 10.1038/nrc2465.
6
State of art and recent developments of anti-cancer strategies based on TRAIL.基于 TRAIL 的抗癌策略的最新进展和现状。
Recent Pat Anticancer Drug Discov. 2012 May 1;7(2):207-17. doi: 10.2174/157489212799972927.
7
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.DR4特异性TRAIL变体在胰腺癌中比野生型TRAIL更有效。
Cancer Biol Ther. 2014;15(12):1658-66. doi: 10.4161/15384047.2014.972183.
8
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.增强半胱天冬酶-8向死亡诱导信号复合物的募集及其在该复合物处的激活，对于化疗药物使人类肝癌细胞对肿瘤坏死因子相关凋亡诱导配体（TRAIL）诱导的凋亡敏感化至关重要。
Cell Death Differ. 2004 Jul;11 Suppl 1:S86-96. doi: 10.1038/sj.cdd.4401437.
9
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.使用促凋亡受体激动剂引导癌细胞自我毁灭。
Nat Rev Drug Discov. 2008 Dec;7(12):1001-12. doi: 10.1038/nrd2637. Epub 2008 Nov 7.
10
Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.雷公藤甲素增强TRAIL对肾细胞癌的杀瘤活性。
FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18.
引用本文的文献
1
Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan.通过丙氨酸扫描介绍TRAIL模拟肽与DR5之间的潜在结合界面。
ACS Med Chem Lett. 2025 Apr 25;16(5):829-836. doi: 10.1021/acsmedchemlett.5c00071. eCollection 2025 May 8.
2
Recent Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Engineering Strategies for Precise Strike Therapy against Tumor.近期用于肿瘤精准打击治疗的肿瘤坏死因子相关凋亡诱导配体工程策略
Biomater Res. 2025 Mar 19;29:0170. doi: 10.34133/bmr.0170. eCollection 2025.
3
Unlocking the Secrets of Extracellular Vesicles: Orchestrating Tumor Microenvironment Dynamics in Metastasis, Drug Resistance, and Immune Evasion.揭开细胞外囊泡的秘密：调控肿瘤微环境在转移、耐药和免疫逃逸中的动态变化
J Cancer. 2024 Oct 14;15(19):6383-6415. doi: 10.7150/jca.98426. eCollection 2024.
4
E3 ubiquitin ligase gene modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes.E3 泛素连接酶基因调节 TNF 诱导的细胞死亡途径，并促进类风湿关节炎成纤维样滑膜细胞的异常增殖。
Front Immunol. 2024 Sep 5;15:1433898. doi: 10.3389/fimmu.2024.1433898. eCollection 2024.
5
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.从隐窝到癌症：结直肠癌发生和治疗策略的整体观点。
Int J Mol Sci. 2024 Aug 30;25(17):9463. doi: 10.3390/ijms25179463.
6
Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma.多种机制导致多发性骨髓瘤中获得性TRAIL耐药。
Cancer Cell Int. 2024 Aug 5;24(1):275. doi: 10.1186/s12935-024-03466-3.
7
TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.肿瘤坏死因子相关凋亡诱导配体：非凋亡信号。
Cells. 2024 Mar 16;13(6):521. doi: 10.3390/cells13060521.
8
Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1.远离宫颈癌：IL-29 通过强力上调 p18、p27 和 TRAILR1，有望成为宫颈癌免疫治疗的细胞因子。
Med Oncol. 2024 Jan 28;41(3):65. doi: 10.1007/s12032-023-02276-3.
9
TRAIL-Sensitizing Effects of Flavonoids in Cancer.黄酮类化合物对癌症的 TRAIL 增敏作用。
Int J Mol Sci. 2023 Nov 22;24(23):16596. doi: 10.3390/ijms242316596.
10
Generation of magnetic biohybrid microrobots based on MSC.sTRAIL for targeted stem cell delivery and treatment of cancer.基于间充质干细胞分泌的肿瘤坏死因子相关凋亡诱导配体生成磁性生物杂交微型机器人用于靶向干细胞递送和癌症治疗。
Cancer Nanotechnol. 2023 May 19;14:54. doi: 10.1186/s12645-023-00203-9.
本文引用的文献
1
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.mapatumumab（一种针对肿瘤坏死因子相关凋亡诱导配体受体1（TRAIL-R1）的全人源激动型单克隆抗体）与紫杉醇和卡铂联合用于晚期非小细胞肺癌患者的II期试验。
Clin Lung Cancer. 2014 May;15(3):188-196.e2. doi: 10.1016/j.cllc.2013.12.005. Epub 2013 Dec 27.
2
Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.c-FLIP 在急性髓系白血病中的预后和治疗相关性。
Br J Haematol. 2013 Jan;160(2):188-98. doi: 10.1111/bjh.12108. Epub 2012 Nov 20.
3
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.Lexatumumab 在实体瘤儿科患者中的 I 期临床试验和药代动力学研究。
J Clin Oncol. 2012 Nov 20;30(33):4141-7. doi: 10.1200/JCO.2012.44.1055. Epub 2012 Oct 15.
4
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.多西妥昔单抗联合一线 mFOLFOX6 加贝伐珠单抗治疗转移性结直肠癌的 Ib 期研究。
Cancer Invest. 2012 Dec;30(10):727-31. doi: 10.3109/07357907.2012.732163. Epub 2012 Oct 12.
5
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.细胞死亡通过 DR5，但不是 DR4，是由骨髓瘤细胞中的 p53 调节的。
Cancer Res. 2012 Sep 1;72(17):4562-73. doi: 10.1158/0008-5472.CAN-12-0487. Epub 2012 Jun 27.
6
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.一项吉妥珠单抗（AMG 479）或康奈妥单抗（AMG 655）联合吉西他滨治疗转移性胰腺癌患者的随机、安慰剂对照 2 期研究。
Ann Oncol. 2012 Nov;23(11):2834-2842. doi: 10.1093/annonc/mds142. Epub 2012 Jun 13.
7
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.抗癌药物的序贯应用通过重新布线细胞凋亡信号网络增强细胞死亡。
Cell. 2012 May 11;149(4):780-94. doi: 10.1016/j.cell.2012.03.031.
8
dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8.dsRNA 通过一种非典型的死亡复合物诱导细胞凋亡，该复合物将 TLR3 与 caspase-8 联系起来。
Cell Death Differ. 2012 Sep;19(9):1482-94. doi: 10.1038/cdd.2012.22. Epub 2012 Mar 16.
9
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.康奈妥单抗联合多柔比星或多柔比星单药一线治疗转移性或局部晚期不可切除的软组织肉瘤的 I/II 期开放标签、双盲研究。
Eur J Cancer. 2012 Mar;48(4):547-63. doi: 10.1016/j.ejca.2011.12.008. Epub 2012 Jan 11.
10
Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.涉及混杂寡聚化受体的信号转导途径中的动力学可以通过受体特异性来确定：TRAIL 诱导细胞凋亡。
Mol Cell Proteomics. 2012 Mar;11(3):M111.013730. doi: 10.1074/mcp.M111.013730. Epub 2012 Jan 2.
Zotero 插件